(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
Tectonic Therapeutic has reported positive topline results from its Phase Ia trial of TX45, a treatment for Group 2 pulmonary hypertension-heart failure with preserved ejection fraction (PH-HFpEF). The trial evaluated safety, tolerability, and pharmacokinetics/
Copyright © 2024 Institute of Good Manufacturing Practices India ( IGMPI® All Rights Reserved. Trademarks are the property of the owner )